ConvaTec
Global medical products and technologies company focused on management of chronic conditions across advanced wound care, ostomy care, continence care and infusion care. Reported ~10,000 employees, $2.142B revenue (2023), eight manufacturing sites and approximately 875 million products manufactured and sold in almost 100 countries.
Industries
Nr. of Employees
small (1-50)
ConvaTec
Patents
Products
Ostomy pouching systems and accessories
Pouching systems, skin barriers and accessories for stoma management designed to reduce leakage and protect peristomal skin.
Advanced wound dressings
Range of dressings for exudate management, infection control and biofilm reduction, including fiber-based absorbents and formulations combining antimicrobial metal ions with biofilm-disrupting agents.
Intermittent urinary catheters
Single-use intermittent catheters intended for self-catheterization, incorporating surface conditioning technologies to assist insertion and user comfort.
Soft-cannula infusion sets with integrated inserters
Disposable infusion sets designed for insulin delivery and other subcutaneous therapies, featuring integrated inserters and soft cannulas for automated insertion.
Indwelling fecal management catheters
Catheter systems intended to manage fecal incontinence and provide access for medication administration in hospital settings.
Neria™ Infusion set
The Neria™ infusion set is a steel needle infusion set designed with ease of use in mind, featuring a 90-degree insertion angle and standard luer-lock connection.
Ostomy pouching systems and accessories
Pouching systems, skin barriers and accessories for stoma management designed to reduce leakage and protect peristomal skin.
Advanced wound dressings
Range of dressings for exudate management, infection control and biofilm reduction, including fiber-based absorbents and formulations combining antimicrobial metal ions with biofilm-disrupting agents.
Intermittent urinary catheters
Single-use intermittent catheters intended for self-catheterization, incorporating surface conditioning technologies to assist insertion and user comfort.
Soft-cannula infusion sets with integrated inserters
Disposable infusion sets designed for insulin delivery and other subcutaneous therapies, featuring integrated inserters and soft cannulas for automated insertion.
Indwelling fecal management catheters
Catheter systems intended to manage fecal incontinence and provide access for medication administration in hospital settings.
Neria™ Infusion set
The Neria™ infusion set is a steel needle infusion set designed with ease of use in mind, featuring a 90-degree insertion angle and standard luer-lock connection.
Services
Enrollment-based patient support program offering education, sample requests and community resources for ostomy and continence patients.
On-demand webinars, downloadable clinical resources and mobile applications to support point-of-care decision making and sample management.
Enrollment-based patient support program offering education, sample requests and community resources for ostomy and continence patients.
On-demand webinars, downloadable clinical resources and mobile applications to support point-of-care decision making and sample management.
Expertise Areas
- Advanced wound care and biofilm management
- Ostomy product design and peristomal skin care
- Continence device development and patient education
- Infusion set design for subcutaneous therapies
Key Technologies
- Carboxymethylcellulose hydrofiber absorbent dressings
- Ionic silver + surfactant + metal-chelator antimicrobial chemistry
- Foam, alginate and hydrocolloid dressing substrates
- Negative pressure wound therapy (NPWT)
News & Updates
Site materials report real-world data showing a median 80% reduction in wound volume over 31 days for patients treated under a wound hygiene protocol designed to manage biofilm and support healing.
Company-reported manufacturing scale of approximately 875 million products manufactured and distribution in almost 100 countries.
Documentation on formulation development states identification of ~250,000 potential formulation combinations and testing of ~60,000 candidates during development of an anti-biofilm dressing chemistry.
Site materials report real-world data showing a median 80% reduction in wound volume over 31 days for patients treated under a wound hygiene protocol designed to manage biofilm and support healing.
Company-reported manufacturing scale of approximately 875 million products manufactured and distribution in almost 100 countries.
Documentation on formulation development states identification of ~250,000 potential formulation combinations and testing of ~60,000 candidates during development of an anti-biofilm dressing chemistry.